Scientists have discovered an RNA-based mechanism that is involved in core hallmarks of a number of accelerated aging conditions and shown that therapies targeting this RNA reverses some of these hallmarks in human cells and extend life spans in mouse models. Read More

Breast cancer progression depends on the interaction between the proliferating breast cancer cells and the biochemical and biophysical properties of the extracellular matrix (ECM). Read More

Researchers from Bioland Laboratory (Guangzhou Regenerative Medicine and Health - Guangdong Laboratory) and the University of Groningen have generated a series of novel biphenyl-benzamides as inhibitors of cell division protein FtsZ with encouraging antibacterial activity. Read More

Guangdong Newopp Biopharmaceuticals has disclosed Son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer. Read More

Apeloa Pharmaceutical and Hangzhou Apeloa Medicine Research Institute have described new N-(benzoyl)-phenylalanine compounds acting as integrin alpha4beta7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease. Read More

Sunshine Lake Pharma has synthesized amide pyrrole compounds reported to be useful for the treatment of liver cancer, cirrhosis and hepatitis B virus (HBV) infection. Read More

Ascentage Pharma has divulged spirocyclic indenes acting as GTPase KRAS (Gly12Cys mutant) inhibitors reported to be useful for the treatment of cancer. Read More

Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) has patented thiazolopyrimidones acting as discoidin domain-containing receptor 1 (DDR1) and/or DDR2 inhibitors reported to be useful for the treatment of atherosclerosis, cancer, cirrhosis, hepatic fibrosis, pulmonary fibrosis, lupus nephritis, osteoarthritis and rheumatoid arthritis, among others. Read More

Merck & Co. is to collaborate with Orna Therapeutics on discovery, development and commercialization in multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Read More

Hepatocellular carcinoma (HCC) still remains a global health challenge as it shows genetic heterogeneity and limited therapy response. In a new study, the cellular responses in HCC that accompany the nearly universal repression of urea cycle enzymes and consequent arginine auxotrophy were investigated, since previous findings demonstrated that that HCC consistently represses urea cycle gene expression and thus become auxotrophic for exogenous arginine becoming severe disease. Read More

The U.S. Department of Defense (DoD) is awarding Codagenix USD 4.4 million for further development of its next-generation tetravalent dengue vaccine candidate CodaVax-DENV. Read More